SEC Charges Swiss Resident in Insider Trading Case Involving Bioverativ Acquisition

14Jun - by Editor - 0 - In STL.News

WASHINGTON DC (STL.News) – The Securities and Exchange Commission (SEC) yesterday filed an amended complaint naming Swiss resident Roland M. Mathys as a defendant in an insider trading case the SEC brought last year alleging that certain unknown traders made approximately $5 million in profits by making timely purchases of Bioverativ, Inc. call options in advance of the January 22, 2018 announcement that Sanofi S.A. would acquire Bioverativ.

The U.S.

Continue reading SEC Charges Swiss Resident in Insider Trading Case Involving Bioverativ Acquisition at STL.News.

Source link